Stockreport

Kyverna Therapeutics Positive Phase 2 Readout: Deep Responses, But Very Small Sample [Seeking Alpha]

Kyverna Therapeutics, Inc.  (KYTX) 
PDF KYTX's miv-cel offers rapid onset, potential for treatment-free remission, and a differentiated safety profile, but results are based on a small, uncontrolled cohort. [Read more]